Report ID: SQMIG35J2106
Bleeding Disorders Treatment Market Size, Share, Growth Analysis, By Disorder Type(Hemophilia A, Hemophilia B, Von Willebrand Disease, Others), By Treatment Type(Recombinant Clotting Factors, Plasma-derived Clotting Factors, Desmopressin, Antifibrinolytics), By Drug Class(Plasma Derived Coagulation Factor (Factor VIII, Factor IX, Factor for Von Willebrand Disease, Activated Prothrombin Complex Concentrate)), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35J2106 |
Region:
Global |
Published Date: June, 2024
Pages:
219
|
Tables:
101 |
Figures:
66
Bleeding Disorders Treatment Market Competitive Landscape
The aggressive surroundings of the Bleeding Disorders Treatment marketplace is dynamic and is characterized via the presence of major pharmaceutical companies and biotechnology corporations striving to establish a sturdy marketplace foothold. Established gamers including Novo Nordisk, Shire (now part of Takeda), and Bayer dominate the marketplace with considerable portfolios of clotting issue merchandise and advancements in remedy alternatives. These enterprise leaders continually spend money on studies and improvement to introduce novel treatment plans, ensuring a aggressive aspect.
Top Player’s Company Profiles
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Biogen Inc.
- CSL Behring (CSL Limited)
- Novo Nordisk A/S
- Pfizer Inc.
- Grifols SA
- Sanofi S.A.
- Johnson & Johnson
- Octapharma AG
Alnylam Pharmaceuticals Inc.
Roche Holding AG
Shire Plc. (earlier Baxalta) (Ireland)
AbbVie Inc.
Wellona Pharma
Sobi International AB
BioMarin Pharmaceutical, Inc.
UniQure NV
Pharming Group N.V.
HEMA BioSciences
Bleeding Disorders Treatment Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
